1.Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment.
Chinese Journal of Hepatology 2022;30(1):103-106
Hepatitis C virus (HCV) RNA can be cleared from the blood circulation by direct antiviral treatment to achieve sustained virologic response (SVR). Studies have shown that SVR after direct antiviral therapy can reduce the incidence of hepatocellular carcinoma; however, monitoring for hepatocellular carcinoma is still needed. This review briefly summarizes and discusses the existing studies on the possible causes of hepatitis C secondary to HCC after antiviral therapy, which is mainly divided into epigenetic alterations and abnormal DNA methylation, HCV-related cirrhosis and abnormal DNA amplification, HBV reactivation, several aspects of occult HCV infection, and the effect of direct antiviral treatment on hepatocellular carcinoma recurrence. In few cases, direct antiviral treatment cannot completely prevent the occurrence and recurrence of hepatitis C-related hepatocellular carcinoma. Therefore, its mechanism needs to be studied and explored, and clinicians should also approach it with caution.
Antiviral Agents/therapeutic use*
;
Carcinoma, Hepatocellular/drug therapy*
;
Hepatitis C/drug therapy*
;
Hepatitis C, Chronic/drug therapy*
;
Humans
;
Liver Neoplasms/etiology*
;
Sustained Virologic Response
2.Clinical observation on effect of shennong xian'ganling capsule in treating chronic hepatitis and liver cirrhosis.
Chinese Journal of Integrated Traditional and Western Medicine 2004;24(5):450-452
Adolescent
;
Adult
;
Aged
;
Capsules
;
Drugs, Chinese Herbal
;
therapeutic use
;
Female
;
Hepatitis B, Chronic
;
complications
;
drug therapy
;
Hepatitis C, Chronic
;
complications
;
drug therapy
;
Humans
;
Liver Cirrhosis
;
drug therapy
;
etiology
;
Male
;
Middle Aged
;
Phytotherapy
4.Chronic Hepatitis C and Insulin Resistance.
The Korean Journal of Gastroenterology 2012;59(4):268-274
Insulin resistance is frequently associated with chronic liver disease, and the interaction between hepatitis C virus (HCV) infection and insulin resistance is a major public health issue, bound to increase in the near term. Because of their potential synergism on liver disease severity, a better understanding of the clinical consequences of the relationship between HCV infection and insulin resistance is needed. This translates into accelerated liver disease progression, reduced response to anti-viral agents and, in susceptible individuals, increased risk of developing type 2 diabetes. HCV may also cause hepatic steatosis, especially in patients infected with genotype 3, although the clinical impact of viral steatosis is debated. Little is known regarding the effect of anti-diabetic agents on HCV infection, and a possible association between use of exogenous insulin or a sulfonylurea agents and the development of hepatocellular carcinoma has recently been reported. Thus, modified lifestyle and pharmacological modalities are urgently warranted in chronic hepatitis C with metabolic alterations.
Antiviral Agents/therapeutic use
;
Diabetes Mellitus, Type 2/complications/drug therapy/metabolism
;
Genotype
;
Hepatitis C, Chronic/*drug therapy/etiology/metabolism
;
Humans
;
Hypoglycemic Agents/therapeutic use
;
Insulin/therapeutic use
;
*Insulin Resistance
;
Liver Cirrhosis/etiology
;
Liver Neoplasms/etiology
;
Sulfonylurea Compounds/therapeutic use
6.Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy.
Li-na MA ; Zhi-min HE ; Wei HUA ; Xin-yue CHEN
Chinese Journal of Hepatology 2013;21(8):594-598
OBJECTIVETo evaluate the therapeutic effects and influencing factors of common antiviral therapy (low-dose interferon plus ribavirin, IFN+RBV) in patients with hepatitis C virus (HCV)-decompensated cirrhosis following splenectomy.
METHODSTwelve patients were treated post-surgery with low-dose IFN (300-500 MIU QOD) or pegylated (Peg)-IFN (50 mug/w) and RBV (0.6-0.9 g/d) for 72 weeks if carrying the lb genotype or 48 weeks if carrying the 2a genotype. All patients were followed-up for 24 weeks after treatment completion to determine the virological response (VR) rates, measured as rapid (R)VR, complete early (cE)VR, 24 hr (24)VR, and sustained (S)VR. Statistical comparisons were made using the t-test or rank sum test, and correlation analyses were made using the Chi-square test. Differences were considered significant at P less than 0.05.
RESULTSAll 12 patients completed the treatment course and follow-up. Three patients could not tolerate the Peg-IFN and were switched to IFN, and six patients developed hemolysis that required RBV dose adjustment. The VR rates were: 25.0%, RVR; 50.0%, cEVR; 16.7%, 24VR; 86.0%, SVR. Only one patient was a non-responder, and only one relapsed. Of the patients who achieved SVR, 100% had shown RVR, 83.3% showed cEVR, and 50.0% showed 24VR, suggesting that RVR and cEVR may effectively predict SVR.
CONCLUSIONSome HCV-decompensated cirrhosis patients may benefit from antiviral therapy following surgical resolution of hypersplenism. The occurrence of RVR and cEVR in these patients is positively correlated with achieving SVR. Physician-patient communication during early antiviral treatment and close clinical monitoring accompanied by psychological counseling throughout promotes success of the treatment approach.
Antiviral Agents ; therapeutic use ; Female ; Hepatitis C, Chronic ; complications ; drug therapy ; Humans ; Interferons ; therapeutic use ; Liver Cirrhosis ; drug therapy ; etiology ; Male ; Middle Aged ; Postoperative Period ; Ribavirin ; therapeutic use ; Splenectomy ; Treatment Outcome
7.Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
Yun Nah LEE ; Soung Won JEONG ; Jae Hee LIM ; Yang Seon RYU ; Seong Ran JEON ; Sang Kyun KIM ; Jae Young JANG ; Young Seok KIM ; Boo Sung KIM ; Mi Oh ROH
The Korean Journal of Hepatology 2010;16(2):187-191
Combined pegylated interferon and ribavirin therapy for chronic hepatitis C infection cause a wide range of side effects, including flu-like syndrome, hematological abnormalities, cardiovascular symptoms, gastrointestinal symptoms, pulmonary dysfunction, depression, and retinopathy. Interferon-alpha has been shown to be related to the development of various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, and type 1 diabetes mellitus (DM). Type 1 DM and thyroid disease respectively develop in 0.08~2.61% and 10~15% of patients treated with combined interferon-alpha and ribavirin for chronic hepatitis C. The coexistence of type 1 DM and autoimmune thyroiditis was rarely reported. We report a case of a 33-year-old female patient with chronic hepatitis C who simultaneously developed diabetic ketoacidosis and autoimmune thyroiditis after treatment with pegylated interferon-alpha 2b and ribavirin.
Adult
;
Antiviral Agents/*adverse effects/therapeutic use
;
Diabetic Ketoacidosis/drug therapy/*etiology
;
Drug Therapy, Combination
;
Female
;
Hepatitis C, Chronic/*drug therapy
;
Humans
;
Insulin/therapeutic use
;
Interferon Alfa-2b/*adverse effects/therapeutic use
;
Polyethylene Glycols/*adverse effects/therapeutic use
;
Ribavirin/*adverse effects/therapeutic use
;
Thyroiditis, Autoimmune/drug therapy/*etiology
;
Thyroxine/therapeutic use
8.Treatment for chronic hepatitis C, more opportunity, more challenge.
Chinese Journal of Hepatology 2009;17(7):481-483
Antiviral Agents
;
administration & dosage
;
therapeutic use
;
Drug Therapy, Combination
;
Genotype
;
Hepatitis B virus
;
drug effects
;
Hepatitis C, Chronic
;
complications
;
drug therapy
;
Humans
;
Interferon-alpha
;
administration & dosage
;
therapeutic use
;
Liver Cirrhosis
;
drug therapy
;
etiology
;
Polyethylene Glycols
;
administration & dosage
;
therapeutic use
;
Protease Inhibitors
;
administration & dosage
;
therapeutic use
;
RNA, Viral
;
blood
;
Ribavirin
;
administration & dosage
;
therapeutic use
;
Treatment Outcome
9.Cryoglobulinemia is an independent factor negatively associated with sustained virological response in chronic hepatitis C patients.
Xiao-hong FAN ; Chi-hong WU ; Li-fen WANG ; Ying-ying ZHENG ; Ying YAO ; Hai-ying LU ; Xiao-yuan XU ; Lai WEI
Chinese Medical Journal 2012;125(22):4014-4017
BACKGROUNDMixed cryoglobulinemia (MC) is one of the most common and severe symptoms in chronic hepatitis C patients. The aim of this study was to investigate whether mixed cryoglobulinemia is a factor associated with sustained virological response in chronic hepatitis C patients treated with combination therapy of pegylated interferon alpha-2a and ribavirin.
METHODSThis is a single-center study including 57 chronic hepatitis C patients who received combination treatments of pegylated interferon alfa-2a and ribavirin. Serum cryoglobulin was detected by cryoprecipitation prior to treatment. Serum hepatitis C virus (HCV) RNA levels were checked before treatment, during the fourth and 12th week of treatment, and during the 24th week after cessation of treatment. The genotype of HCV was determined at baseline. Logistic regression analysis was used to assess the factors associated with sustained virological response.
RESULTSTwenty-five patients were with MC (43.9%). Twenty-four weeks after cessation of antiviral treatment, sustained virological response achievement in MC(+) patients was significantly lower than that in MC(-) patients (32.0% vs. 75.0%, P = 0.001). Univariate Logistic regression analysis and multivariate Logistic regression analysis found that only MC (odds ratio: 6.375; 95% CI: 1.998- 20.343, P = 0.002) was negatively associated with sustained virological response achievement.
CONCLUSIONMC is an independent factor negatively associated with sustained virological response in chronic hepatitis C patients treated with pegylated interferon alpha-2a and ribavirin.
Adolescent ; Adult ; Aged ; Cryoglobulinemia ; etiology ; metabolism ; Cryoglobulins ; metabolism ; Female ; Hepatitis C, Chronic ; blood ; drug therapy ; Humans ; Interferon-alpha ; therapeutic use ; Male ; Middle Aged ; Polyethylene Glycols ; therapeutic use ; Recombinant Proteins ; therapeutic use ; Ribavirin ; therapeutic use ; Young Adult
10.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
Yuri CHO ; Eun Ju CHO ; Jeong Hoon LEE ; Su Jong YU ; Jung Hwan YOON ; Yoon Jun KIM
Clinical and Molecular Hepatology 2015;21(4):358-364
BACKGROUND/AIMS: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A new era of direct-acting antivirals is now dawning in Korea. Early experience of applying sofosbuvir-based therapy to CHC patients in Korea is reported herein. METHODS: Data on efficacy and safety were collected for CHC patients treated with a combination of sofosbuvir plus ribavirin or sofosbuvir/ledipasvir with or without ribavirin. RESULTS: This retrospective study included 25 consecutive patients who received sofosbuvir-based therapy (19 with genotype 1b and 6 with genotype 2) at Seoul National University Hospital from May 2014 to April 2015. A virologic response was achieved at week 4 by 85.7% and 80% of the patients with genotypes 1b and 2, respectively. The HCV-RNA level decreased more slowly in IFN-experienced than in treatment-naive patients with genotype 1b. However, the sustained virologic response at week 12 (SVR12) rate did not differ among these patients, and was as high as 100%. The presence of cirrhosis significantly increased the risk of a virologic response failure at week 4 (OR, 11.0; P=0.011) among patients with HCV genotype 1b. Only five patients (20%) experienced minor adverse events, including grade 1 fatigue and headache. The hemoglobin level decreased slightly after sofosbuvir-based therapy, but there was no case of premature discontinuation of this therapy. CONCLUSIONS: In a real clinical practice, sofosbuvir-based therapy for CHC patients in Korea achieved optimal antiviral efficacy with insignificant adverse events. Long-term follow-up data are warranted to ensure the sustained antiviral efficacy and long-term safety of sofosbuvir-based IFN-free therapy.
Adult
;
Aged
;
Aged, 80 and over
;
Antiviral Agents/adverse effects/*therapeutic use
;
Drug Therapy, Combination
;
Fatigue/etiology
;
Female
;
Genotype
;
Headache/etiology
;
Hemoglobins/analysis
;
Hepacivirus/genetics
;
Hepatitis C, Chronic/complications/*drug therapy/virology
;
Humans
;
Liver Cirrhosis/complications/diagnosis
;
Male
;
Middle Aged
;
RNA, Viral/blood
;
Republic of Korea
;
Retrospective Studies
;
Ribavirin/therapeutic use
;
Sofosbuvir/adverse effects/*therapeutic use
;
Treatment Outcome